Age-Stratified Survival Patterns in Adults with Nonmalignant Intracranial Meningioma: A Population-Based SEER Cohort Study.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42710835.
- Also identified by DOI 10.1016/j.wneu.2026.125302.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nonmalignant intracranial meningiomas are common primary CNS tumors with favorable prognosis, yet survival patterns across adulthood remain incompletely characterized. This study aims to evaluate age-stratified overall survival according to sex, race, ethnicity, tumor size, and surgical history. This retrospective cohort study used the Surveillance, Epidemiology, and End Results (SEER) database to identify adults (≥18 years) diagnosed with nonmalignant intracranial meningioma from 2004 to 2022. The primary outcome was overall survival. Age-stratified Kaplan-Meier analyses and multivariable Cox proportional hazards models were constructed across five age groups (<50, 50-59, 60-69, 70-79, ≥80). Among 48,964 patients (75% female), mortality increased progressively with age, while surgical resection rates declined from 39% (<50 years) to 5.8% (≥80 years). Female sex was independently associated with improved survival across all age strata (HR:0.50-0.75; all p<0.001), though the magnitude attenuated with advancing age. Black patients demonstrated higher mortality than White patients in age groups under 80 years (HR:1.28-1.48; p<0.001). Surgical management was associated with improved survival across all age groups, with the largest absolute 10-year survival differences observed in patients with tumors ≥40 mm (range: 9.8%-20%) and the smallest in patients aged 70-79 years with tumors <20 mm (1.6%, p = 0.286). Tumor size ≥40 mm was the strongest independent mortality predictor (HR:1.47-1.93). Survival in nonmalignant intracranial meningioma varies across adulthood. Age-stratified analysis reveals heterogeneity in sex, racial, tumor-size, and treatment-related survival. These findings support individualized prognostic assessment incorporating age, tumor burden, and clinical context.